Melanoma Clinical Trial
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Summary
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.
The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Eligibility Criteria
Inclusion Criteria:
Index date: First line therapy start date recorded in the database between 20 November 2015 and 03 January 2022
Age 18 years or older in the year of the index first m-melanoma diagnostic claim
Patients with pathologic stages III to IV at initial diagnosis on or after 01 January 2011, or patients who develop a locoregional or distant recurrence on or after 01 January 2011
Patients with confirmed BRAF V600 activating mutation will be included - BRAF mutational testing / genetic analysis results needed (testing status, mutation type, test result). Patients having tested positive for the mutation at any time will be included. Date of sample collection and date of test result received by provider will be collected
Exclusion Criteria:
Patients with a record of other primary malignant tumors in the year before diagnosis of m-melanoma
Patients with only 1 m-melanoma diagnosis
Patients with insufficient data for analysis (ie, <1 month of clinical activity during the prior period, had <1 month of clinical activity during the post period)
Patients currently enrolled in a clinical trial
Patients that received treatment for m-melanoma prior to the study index date
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10017, United States
How clear is this clinincal trial information?